Asia Pacific Pulmonary Arterial Hypertension Market Forecast to 2028 - COVID-19 Impact and Regional Analysis by Drugs [Endothelin Receptor Antagonists (ERAs), Prostacyclin and Prostacyclin Analogs, sGC Stimulators, and pde-5 Dipsticks], Type (Branded and Generics), Route of Administration (Oral, Intravenous/Subcutaneous, and Inhalational), and Distribution Channel (Hospital Pharmacies and Clinics, Online Pharmacies, and Retail Pharmacies)
The Asia Pacific pulmonary arterial hypertension market is expected to grow from US$ 1,531.47 million in 2022 to US$ 2,236.62 million by 2028; it is estimated to grow at a CAGR of 6.5% from 2022 to 2028.
Rising Clinical Trials for Drug Development to Treat Pulmonary Arterial Hypertension to Fuel Asia Pacific Pulmonary Arterial Hypertension Market in Coming Years
Growing advancements in understanding the genetic and molecular mechanisms that drive the pathogenesis of the disease are supporting the development of PAH therapies. With the growing knowledge, the treatment strategies will continue to evolve and diversify from the current paradigm focused on vasoconstriction. Clinical trials are exploring the clinical efficacy of novel delivery devices and their utility in the treatment of other forms of pulmonary hypertension and combination therapies. This is likely to be the standard for clinical trials in the coming years. Rising clinical trials for drug development to treat pulmonary arterial hypertension are expected to fuel the Asia Pacific pulmonary arterial hypertension market during the forecast period.
Asia Pacific Pulmonary Arterial Hypertension Market Overview
The Asia Pacific pulmonary arterial hypertension market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. China held the largest market share in 2021, and India is expected to exhibit significant market growth during the forecast period. In China, a large-scale nationwide pulmonary arterial hypertension (PAH) registry—including over 2,000 patients and detailed data on prescription patterns and treatment—was published in 2022, which reported that congenital heart disease-related PAH (45.2%) was reportedly the most common type of PAH in the country. However, the accessibility of PAH drugs in China remains poor, with only a few cities including the costs of drugs in their medical insurance. Hence, financially unstable patients suffering from PAH do not complete the entire treatment period.
Further, the presence of key players and rising pulmonary arterial hypertension drug development in the country are boosting the market in China. Manufacturers focus on expanding their strategic global presence and specialized expertise with exclusive technological capabilities, leading to better PAH drug availability in China. For instance, Toray and Shenzhen Main Luck Pharmaceuticals are preparing to launch Careload in early 2023. In September 2022, Toray Industries, Inc. announced that it had received approval from the National Medical Products Administration (NMPA) in China for Careload tablets to treat pulmonary arterial hypertension. Similarly, in February 2021, Aerami Therapeutics, Inc. announced the signing of an exclusive license and development agreement with Hangzhou Chance Pharmaceuticals Co. Ltd. to develop and commercialize Aerami’s drug-device combination product candidate (AER-901) for the treatment of PAH in mainland China, Hong Kong, Macau, and Taiwan. Furthermore, The World Bank Group reported that the current healthcare expenditure of China grew from 4.94% of the total GDP in 2015 to 5.35% in 2019, which is boosting drug development in the country. Hence, the high prevalence of PAH, a rise in healthcare expenditure, and advancements by key players are expected to propel the growth of the pulmonary arterial hypertension market in China.
Asia Pacific Pulmonary Arterial Hypertension Market Revenue and Forecast to 2028 (US$ Billion)
Asia Pacific Pulmonary Arterial Hypertension Market Segmentation
The Asia Pacific pulmonary arterial hypertension market is segmented on the basis of drugs, type, route of administration, distribution channel, and country.
Based on drugs, the Asia Pacific pulmonary arterial hypertension market is segmented into endothelin receptor antagonists (ERAs), prostacyclin and prostacyclin analogs, sGC stimulators, and pde-5 dipsticks. In 2022, the prostacyclin and prostacyclin analogs segment registered the largest share in the Asia Pacific pulmonary arterial hypertension market.
Based on type, the Asia Pacific pulmonary arterial hypertension market is bifurcated into branded and generics. In 2022, the branded segment registered a larger share in the Asia Pacific pulmonary arterial hypertension market.
Based on route of administration, the Asia Pacific pulmonary arterial hypertension market is segmented into oral, intravenous/subcutaneous, and inhalational. In 2022, the oral segment registered the largest share in the Asia Pacific pulmonary arterial hypertension market.
Based on distribution channel, the Asia Pacific pulmonary arterial hypertension market is segmented into hospital pharmacies and clinics, online pharmacies, and retail pharmacies. In 2022, the hospital pharmacies and clinics segment registered the largest share in the Asia Pacific pulmonary arterial hypertension market.
Based on country, the Asia Pacific pulmonary arterial hypertension market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. In 2022, China registered the largest share in the Asia Pacific pulmonary arterial hypertension market.
Bayer AG, Gilead Sciences Inc, GSK Plc, Johnson & Johnson, Lupin Ltd, Novartis AG, Pfizer Inc, and Teva Pharmaceutical Industries Ltd are the leading companies operating in the Asia Pacific pulmonary arterial hypertension market.
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Asia Pacific Pulmonary Arterial Hypertension Market – By Drugs
1.3.2 Asia Pacific Pulmonary Arterial Hypertension Market – By Type
1.3.3 Asia Pacific Pulmonary Arterial Hypertension Market – By Route of Administration
1.3.4 Asia Pacific Pulmonary Arterial Hypertension Market – By Distribution Channel
1.3.5 Asia Pacific Pulmonary Arterial Hypertension Market – By Country
2. Asia Pacific Pulmonary Arterial Hypertension Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Asia Pacific Pulmonary Arterial Hypertension Market – Market Landscape
4.1 Overview
4.2 Asia Pacific PEST Analysis
4.3 Experts Opinion
5. Asia Pacific Pulmonary Arterial Hypertension Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Growing Incidence of Pulmonary Arterial Hypertension
5.1.2 Rising Approvals of Pulmonary Arterial Hypertension Drugs
5.2 Market Restraints
5.2.1 Side Effects of Drugs Used for Treatment of Pulmonary Arterial Hypertension
5.3 Market Opportunities
5.3.1 Availability of Generics at Affordable Costs Due to Growing Patent Expiration
5.4 Future Trend
5.4.1 Rising Clinical Trials for Drugs Development to Treat Pulmonary Arterial Hypertension
5.5 Impact analysis
6. Pulmonary Arterial Hypertension Market – Asia Pacific Analysis
6.1 Asia Pacific Pulmonary Arterial Hypertension Market Revenue Forecast and Analysis
7. Asia Pacific Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 – by Drugs
7.1 Overview
7.2 Asia Pacific Pulmonary Arterial Hypertension Market Revenue Share, by Drugs 2021 & 2028 (%)
7.3 Endothelin Receptor Antagonists (ERAs)
7.3.1 Overview
7.3.2 Endothelin Receptor Antagonists (ERAs): Asia Pacific Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
7.4 Prostacyclin and Prostacyclin Analogs
7.4.1 Overview
7.4.2 Prostacyclin and Prostacyclin Analogs: Asia Pacific Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
7.5 SGC Stimulators
7.5.1 Overview
7.5.2 sGC Stimulators: Asia Pacific Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
7.6 Pde-5 Dipsticks
7.6.1 Overview
7.6.2 Pde-5 Dipsticks: Asia Pacific Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
8. Asia Pacific Pulmonary Arterial Hypertension Market Analysis and Forecasts to 2028 – by Type
8.1 Overview
8.2 Asia Pacific Pulmonary Arterial Hypertension Market, by Type 2021 & 2028 (%)
8.3 Branded
8.3.1 Overview
8.3.2 Branded: Asia Pacific Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
8.4 Generics
8.4.1 Overview
8.4.2 Generics: Asia Pacific Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
9. Asia Pacific Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 – by Route of Administration
9.1 Overview
9.2 Asia Pacific Pulmonary Arterial Hypertension Market Revenue Share, by Route of Administration 2021 & 2028 (%)
9.3 Oral
9.3.1 Overview
9.3.2 Oral: Asia Pacific Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
9.4 Intravenous/ Subcutaneous
9.4.1 Overview
9.4.2 Intravenous/ Subcutaneous: Asia Pacific Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
9.5 Inhalational
9.5.1 Overview
9.5.2 Inhalational: Asia Pacific Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
10. Asia Pacific Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 – by Distribution Channel
10.1 Overview
10.2 Asia Pacific Pulmonary Arterial Hypertension Market Revenue Share, by Distribution Channel 2021 & 2028 (%)
10.3 Hospital Pharmacies and Clinics
10.3.1 Overview
10.3.2 Hospital Pharmacies and Clinics: Asia Pacific Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
10.4 Online Pharmacies
10.4.1 Overview
10.4.2 Online Pharmacies: Asia Pacific Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
10.5 Retail Pharmacies
10.5.1 Overview
10.5.2 Retail Pharmacies: Asia Pacific Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
11. Asia Pacific Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 – Country Analysis
11.1 Overview
11.1.1 Asia Pacific: Pulmonary Arterial Hypertension Market, by Country, 2021 & 2028 (%)
11.1.1.1 China: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.1.1 Overview
11.1.1.1.2 China: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.1.3 China: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)
11.1.1.1.4 China: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)
11.1.1.1.5 China Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)
11.1.1.1.6 China Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)
11.1.1.2 Japan: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.2.1 Overview
11.1.1.2.2 Japan: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.2.3 Japan: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)
11.1.1.2.4 Japan: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)
11.1.1.2.5 Japan: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)
11.1.1.2.6 Japan: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)
11.1.1.3 India: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.3.1 Overview
11.1.1.3.2 India: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.3.3 India: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)
11.1.1.3.4 India: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)
11.1.1.3.5 India: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)
11.1.1.3.6 India: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)
11.1.1.4 South Korea: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.4.1 Overview
11.1.1.4.2 South Korea: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.4.3 South Korea: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)
11.1.1.4.4 South Korea: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)
11.1.1.4.5 South Korea: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)
11.1.1.4.6 South Korea: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)
11.1.1.5 Australia: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.5.1 Overview
11.1.1.5.2 Australia: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.5.3 Australia: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)
11.1.1.5.4 Australia: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)
11.1.1.5.5 Australia: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)
11.1.1.5.6 Australia: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)
11.1.1.6 Rest of Asia Pacific: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.6.1 Overview
11.1.1.6.2 Rest of Asia Pacific: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.6.3 Rest of Asia Pacific: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)
11.1.1.6.4 Rest of Asia Pacific: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)
11.1.1.6.5 Rest of Asia Pacific: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)
11.1.1.6.6 Rest of Asia Pacific: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)
12. Asia Pacific Pulmonary Arterial Hypertension Market – Industry Landscape
12.1 Overview
12.2 Organic Developments
12.2.1 Overview
12.3 Inorganic Developments
12.3.1 Overview
13. Company Profiles
13.1 Johnson & Johnson
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Gilead Sciences Inc
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Bayer AG
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Novartis AG
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 GSK Plc
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Teva Pharmaceutical Industries Ltd
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Lupin Ltd
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Pfizer Inc
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
14. Appendix
14.1 About The Insight Partners
14.2 Glossary of Terms
LIST OF TABLES
Table 1. Asia Pacific Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 2. China Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)
Table 3. China Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 4. China Pulmonary Arterial Hypertension Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)
Table 5. China Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)
Table 6. Japan Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)
Table 7. Japan Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 8. Japan Pulmonary Arterial Hypertension Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)
Table 9. Japan Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)
Table 10. India Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)
Table 11. India Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 12. India Pulmonary Arterial Hypertension Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)
Table 13. India Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)
Table 14. South Korea Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)
Table 15. South Korea Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 16. South Korea Pulmonary Arterial Hypertension Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)
Table 17. South Korea Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)
Table 18. Australia Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)
Table 19. Australia Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 20. Australia Pulmonary Arterial Hypertension Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)
Table 21. Australia Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)
Table 22. Rest of Asia Pacific Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)
Table 23. Rest of Asia Pacific Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 24. Rest of Asia Pacific Pulmonary Arterial Hypertension Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)
Table 25. Rest of Asia Pacific Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)
Table 26. Organic Developments in the Asia Pacific pulmonary arterial hypertension market
Table 27. Inorganic Developments in the Asia Pacific pulmonary arterial hypertension market
Table 28. Glossary of Terms
LIST OF FIGURES
Figure 1. Asia Pacific Pulmonary Arterial Hypertension Market Segmentation
Figure 2. Asia Pacific Pulmonary Arterial Hypertension Market – By Country
Figure 3. Asia Pacific Pulmonary Arterial Hypertension Market Overview
Figure 4. Prostacyclin and Prostacyclin Analogs Segment Held Largest Share by Drugs of the Asia Pacific Pulmonary Arterial Hypertension Market
Figure 5. China to Show Significant Growth During Forecast Period
Figure 6. Asia Pacific: PEST Analysis
Figure 7. Experts Opinion
Figure 8. Asia Pacific Pulmonary Arterial Hypertension Market Impact Analysis of Drivers and Restraint
Figure 9. Asia Pacific Pulmonary Arterial Hypertension Market– Revenue Forecast and Analysis – 2019 - 2028
Figure 10. Asia Pacific Pulmonary Arterial Hypertension Market Revenue Share, by Drugs 2021 & 2028 (%)
Figure 11. Endothelin Receptor Antagonists (ERAs): Asia Pacific Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
Figure 12. Prostacyclin and Prostacyclin Analogs: Asia Pacific Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
Figure 13. sGC Stimulators: Asia Pacific Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
Figure 14. Pde-5 Dipsticks: Asia Pacific Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
Figure 15. Asia Pacific Pulmonary Arterial Hypertension Market, by Type 2021 & 2028 (%)
Figure 16. Branded: Asia Pacific Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
Figure 17. Generics: Asia Pacific Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
Figure 18. Asia Pacific Pulmonary Arterial Hypertension Market Revenue Share, by Route of Administration 2021 & 2028 (%)
Figure 19. Oral: Asia Pacific Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
Figure 20. Intravenous/ Subcutaneous: Asia Pacific Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
Figure 21. Inhalational: Asia Pacific Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
Figure 22. Asia Pacific Pulmonary Arterial Hypertension Market Revenue Share, by Distribution Channel 2021 & 2028 (%)
Figure 23. Hospital Pharmacies and Clinics: Asia Pacific Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
Figure 24. Online Pharmacies: Asia Pacific Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
Figure 25. Retail Pharmacies: Asia Pacific Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
Figure 26. Asia Pacific: Pulmonary Arterial Hypertension Market, by Key Country – Revenue (2021) (US$ Million)
Figure 27. China: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
Figure 28. Japan: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
Figure 29. India: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
Figure 30. South Korea: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
Figure 31. Australia: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
Figure 32. Rest of Asia Pacific: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
- Bayer AG
- Gilead Sciences Inc
- GSK Plc
- Johnson & Johnson
- Lupin Ltd
- Novartis AG
- Pfizer Inc
- Teva Pharmaceutical Industries Ltd
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific pulmonary arterial hypertension market.
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific pulmonary arterial hypertension market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the pulmonary arterial hypertension market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution